VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q73566215  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241221010737.0
008     241221nneanz||abbn n and d
035 ‎‡a  (WKP)Q73566215‏
024 ‎‡a  0000-0001-6732-3726‏ ‎‡2  orcid‏
024 ‎‡a  7402256547‏ ‎‡2  scopus‏
035 ‎‡a  (OCoLC)Q73566215‏
100 0 ‎‡a  Donald H Berry‏ ‎‡c  researcher‏ ‎‡9  en‏
400 0 ‎‡a  Donald H Berry‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
670 ‎‡a  Author's Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia‏
670 ‎‡a  Author's Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104‏
670 ‎‡a  Author's Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer‏
670 ‎‡a  Author's Adjuvant chemotherapy in older women with early-stage breast cancer‏
670 ‎‡a  Author's Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical T‏
670 ‎‡a  Author's Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography.‏
670 ‎‡a  Author's Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies‏
670 ‎‡a  Author's Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).‏
670 ‎‡a  Author's Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial‏
670 ‎‡a  Author's Electrochemistry of Ruthenium Bis‏
670 ‎‡a  Author's Electrochemistry of Ruthenium Bis(imino)pyridine Compounds: Evidence for an ECE Mechanism and Isolation of Mono and Dicationic Complexes.‏
670 ‎‡a  Author's Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer‏
670 ‎‡a  Author's Evidence for ligand non-innocence in a formally ruthenium‏
670 ‎‡a  Author's Evidence for ligand non-innocence in a formally ruthenium(I) hydride complex‏
670 ‎‡a  Author's Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.‏
670 ‎‡a  Author's Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.‏
670 ‎‡a  Author's In Reply:‏
670 ‎‡a  Author's Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.‏
670 ‎‡a  Author's Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806‏
670 ‎‡a  Author's Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer‏
670 ‎‡a  Author's Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343‏
670 ‎‡a  Author's Magnetism and EPR Studies of Binuclear Ruthenium Hydride Binuclear Species Bearing Redox-Active Ligands‏
670 ‎‡a  Author's MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial‏
670 ‎‡a  Author's Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.‏
670 ‎‡a  Author's Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.‏
670 ‎‡a  Author's Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an‏
670 ‎‡a  Author's Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu‏
670 ‎‡a  Author's Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial‏
670 ‎‡a  Author's Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et al‏
670 ‎‡a  Author's Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes‏
670 ‎‡a  Author's Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.‏
670 ‎‡a  Author's Structure and reactivity of bis‏
670 ‎‡a  Author's Structure and reactivity of bis(silyl) dihydride complexes (PMe(3))(3)Ru(SiR(3))(2)(H)(2): model compounds and real intermediates in a dehydrogenative C-Si bond forming reaction‏
670 ‎‡a  Author's Synthesis and reactivity of silyl ruthenium complexes: the importance of trans effects in C-H activation, Si-C bond formation, and dehydrogenative coupling of silanes‏
670 ‎‡a  Author's Synthesis and structure of ruthenium-silylene complexes: activation of Si-Cl bonds in N-heterocyclic silanes‏
670 ‎‡a  Author's Synthesis of tridentate 2,6-bis(imino)pyridyl ruthenium(II) complexes with N-heterocyclic carbene ligands: activation of imidazolium salts‏
670 ‎‡a  Author's Tandem beta-C-H activation/Si-H elimination reactions: stabilization of C-H activation products by beta-agostic Si-H interactions‏
670 ‎‡a  Author's The first optically active polygermanes: preferential screw sense helicity of enantiopure chiral-substituted aryl polygermanes and comparison with analogous polysilanes‏
670 ‎‡a  Author's The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer‏
670 ‎‡a  Author's Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience‏
909 ‎‡a  (scopus) 7402256547‏ ‎‡9  1‏
909 ‎‡a  (orcid) 0000000167323726‏ ‎‡9  1‏
912 ‎‡a  inreply‏ ‎‡A  In Reply:‏ ‎‡9  1‏
919 ‎‡a  1opticallyactivepolygermanespreferentialscrewsensehelicityofenantiopurechiralsubstitutedarylpolygermanesandcomparisonwithanalogouspolysilanes‏ ‎‡A  The first optically active polygermanes: preferential screw sense helicity of enantiopure chiral-substituted aryl polygermanes and comparison with analogous polysilanes‏ ‎‡9  1‏
919 ‎‡a  tandembeta100hactivationsiheliminationreactionsstabilizationof100hactivationproductsbybetaagosticsihinteractions‏ ‎‡A  Tandem beta-C-H activation/Si-H elimination reactions: stabilization of C-H activation products by beta-agostic Si-H interactions‏ ‎‡9  1‏
919 ‎‡a  synthesisoftridentate26bisiminopyridylruthenium2complexeswithnheterocycliccarbeneligandsactivationofimidazoliumsalts‏ ‎‡A  Synthesis of tridentate 2,6-bis(imino)pyridyl ruthenium(II) complexes with N-heterocyclic carbene ligands: activation of imidazolium salts‏ ‎‡9  1‏
919 ‎‡a  synthesisandstructureofrutheniumsilylenecomplexesactivationofsi150bondsinnheterocyclicsilanes‏ ‎‡A  Synthesis and structure of ruthenium-silylene complexes: activation of Si-Cl bonds in N-heterocyclic silanes‏ ‎‡9  1‏
919 ‎‡a  synthesisandreactivityofsilylrutheniumcomplexestheimportanceoftranseffectsin100hactivationsi100bondformationanddehydrogenativecouplingofsilanes‏ ‎‡A  Synthesis and reactivity of silyl ruthenium complexes: the importance of trans effects in C-H activation, Si-C bond formation, and dehydrogenative coupling of silanes‏ ‎‡9  1‏
919 ‎‡a  lumpectomyplustamoxifenwithorwithoutirradiationinwomenage70yearsorolderwithearlybreastcancerlongtermfollowupofcalgb‏ ‎‡A  Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343‏ ‎‡9  1‏
919 ‎‡a  lumpectomyplustamoxifenwithorwithoutirradiationinwomen70yearsofageorolderwithearlybreastcancer‏ ‎‡A  Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer‏ ‎‡9  1‏
919 ‎‡a  interleukin6multidrugresistanceprotein1expressionandresponsetopaclitaxelinwomenwithmetastaticbreastcancerresultsofcancerandleukemiagroupbtrial159806‏ ‎‡A  Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806‏ ‎‡9  1‏
919 ‎‡a  influenceofactivationstateoferbb2her2onresponsetoadjuvantcyclophosphamidedoxorubicinandfluorouracilforstage2nodepositivebreastcancerstudy8541fromthecancerandleukemiagroupb‏ ‎‡A  Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.‏ ‎‡9  1‏
919 ‎‡a  improvedoutcomesfromaddingsequentialpaclitaxelbutnotfromescalatingdoxorubicindoseinanadjuvantchemotherapyregimenforpatientswithnodepositiveprimarybreastcancer‏ ‎‡A  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.‏ ‎‡9  1‏
919 ‎‡a  failureofhigherdosepaclitaxeltoimproveoutcomeinpatientswithmetastaticbreastcancercancerandleukemiagroupbtrial‏ ‎‡A  Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.‏ ‎‡9  1‏
919 ‎‡a  evidenceforligandnoninnocenceinaformallyruthenium1hydridecomplex‏ ‎‡A  Evidence for ligand non-innocence in a formally ruthenium(I) hydride complex‏ ‎‡9  1‏
919 ‎‡a  evidenceforligandnoninnocenceinaformallyruthenium‏ ‎‡A  Evidence for ligand non-innocence in a formally ruthenium‏ ‎‡9  1‏
919 ‎‡a  estrogenreceptorstatusandoutcomesofmodernchemotherapyforpatientswithnodepositivebreastcancer‏ ‎‡A  Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer‏ ‎‡9  1‏
919 ‎‡a  electrochemistryofrutheniumbisiminopyridinecompoundsevidenceforanecemechanismandisolationofmonoanddicationiccomplexes‏ ‎‡A  Electrochemistry of Ruthenium Bis(imino)pyridine Compounds: Evidence for an ECE Mechanism and Isolation of Mono and Dicationic Complexes.‏ ‎‡9  1‏
919 ‎‡a  electrochemistryofrutheniumbis‏ ‎‡A  Electrochemistry of Ruthenium Bis‏ ‎‡9  1‏
919 ‎‡a  effectofpembrolizumabplusneoadjuvantchemotherapyonpathologiccompleteresponseinwomenwithearlystagebreastcancerananalysisoftheongoingphase2adaptivelyrandomized1spy2trial‏ ‎‡A  Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial‏ ‎‡9  1‏
919 ‎‡a  comparisonofdoxorubicinandcyclophosphamideversussingleagentpaclitaxelasadjuvanttherapyforbreastcancerinwomenwith0to3positiveaxillarynodescalgb40101alliance‏ ‎‡A  Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).‏ ‎‡9  1‏
919 ‎‡a  collaborativemodelingofthebenefitsandharmsassociatedwithdifferentusbreastcancerscreeningstrategies‏ ‎‡A  Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies‏ ‎‡9  1‏
919 ‎‡a  benefitsharmsandcostsforbreastcancerscreeningafterusimplementationofdigitalmammography‏ ‎‡A  Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography.‏ ‎‡9  1‏
919 ‎‡a  associationofeventfreeanddistantrecurrencefreesurvivalwithindividuallevelpathologiccompleteresponseinneoadjuvanttreatmentofstages2and3breastcancer3yearfollowupanalysisforthe1spy2adaptivelyrandomizedclinicalt‏ ‎‡A  Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical T‏ ‎‡9  1‏
919 ‎‡a  adjuvantchemotherapyinolderwomenwithearlystagebreastcancer‏ ‎‡A  Adjuvant chemotherapy in older women with early-stage breast cancer‏ ‎‡9  1‏
919 ‎‡a  adjuvantchemotherapyinolderandyoungerwomenwithlymphnodepositivebreastcancer‏ ‎‡A  Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer‏ ‎‡9  1‏
919 ‎‡a  adherenceandpersistencewithoraladjuvantchemotherapyinolderwomenwithearlystagebreastcancerincalgb49907adherencecompanionstudy60104‏ ‎‡A  Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104‏ ‎‡9  1‏
919 ‎‡a  adaptiverandomizedstudyofidarubicinandcytarabineversustroxacitabineandcytarabineversustroxacitabineandidarubicininuntreatedpatients50yearsorolderwithadversekaryotypeacutemyeloidleukemia‏ ‎‡A  Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia‏ ‎‡9  1‏
919 ‎‡a  structureandreactivityofbissilyldihydridecomplexespme33rusir32h2modelcompoundsandrealintermediatesinadehydrogenative100sibondformingreaction‏ ‎‡A  Structure and reactivity of bis(silyl) dihydride complexes (PMe(3))(3)Ru(SiR(3))(2)(H)(2): model compounds and real intermediates in a dehydrogenative C-Si bond forming reaction‏ ‎‡9  1‏
919 ‎‡a  structureandreactivityofbis‏ ‎‡A  Structure and reactivity of bis‏ ‎‡9  1‏
919 ‎‡a  6cyclesofdoxorubicinandcyclophosphamideorpaclitaxelarenotsuperiorto4cyclesasadjuvantchemotherapyforbreastcancerinwomenwith0to3positiveaxillarynodescancerandleukemiagroupb40101‏ ‎‡A  Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.‏ ‎‡9  1‏
919 ‎‡a  reportofaphase12studyofacombinationofazacitidineandcytarabineinacutemyelogenousleukemiaandhighriskmyelodysplasticsyndromes‏ ‎‡A  Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes‏ ‎‡9  1‏
919 ‎‡a  replytopgtsoutsouetalokaidarpersonetalandacourdietal‏ ‎‡A  Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et al‏ ‎‡9  1‏
919 ‎‡a  randomizedtrialofstandardadjuvantchemotherapyregimensversuscapecitabineinolderwomenwithearlybreastcancer10yearupdateofthecalgb49907trial‏ ‎‡A  Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial‏ ‎‡9  1‏
919 ‎‡a  randomizedtrialofdosedenseversusconventionallyscheduledandsequentialversusconcurrentcombinationchemotherapyaspostoperativeadjuvanttreatmentofnodepositiveprimarybreastcancer1reportofintergrouptrialc9741cancerandleu‏ ‎‡A  Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu‏ ‎‡9  1‏
919 ‎‡a  randomizedphase3trialofweeklycomparedwithevery3weekspaclitaxelformetastaticbreastcancerwithtrastuzumabforallher2overexpressorsandrandomassignmenttotrastuzumabornotinher2nonoverexpressorsfinalresultsofcanceran‏ ‎‡A  Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an‏ ‎‡9  1‏
919 ‎‡a  racialdifferencesinclinicaloutcomesfrommetastaticbreastcancerapooledanalysisofcalgb9342and9840cancerandleukemiagroupb‏ ‎‡A  Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.‏ ‎‡9  1‏
919 ‎‡a  naturalhistoryofmorethan20yearsofnodepositiveprimarybreastcarcinomatreatedwithcyclophosphamidemethotrexateandfluorouracilbasedadjuvantchemotherapyastudybythecancerandleukemiagroupb‏ ‎‡A  Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.‏ ‎‡9  1‏
919 ‎‡a  mk2206andstandardneoadjuvantchemotherapyimprovesresponseinpatientswithhumanepidermalgrowthfactorreceptor2positiveandorhormonereceptornegativebreastcancersinthe1spy2trial‏ ‎‡A  MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial‏ ‎‡9  1‏
919 ‎‡a  magnetismandeprstudiesofbinuclearrutheniumhydridebinuclearspeciesbearingredoxactiveligands‏ ‎‡A  Magnetism and EPR Studies of Binuclear Ruthenium Hydride Binuclear Species Bearing Redox-Active Ligands‏ ‎‡9  1‏
919 ‎‡a  toxicityofolderandyoungerpatientstreatedwithadjuvantchemotherapyfornodepositivebreastcancerthecancerandleukemiagroupbexperience‏ ‎‡A  Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience‏ ‎‡9  1‏
919 ‎‡a  neoadjuvantmodelisstillthefuturefordrugdevelopmentinbreastcancer‏ ‎‡A  The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer‏ ‎‡9  1‏
996 ‎‡2  NII|DA00561529‏
996 ‎‡2  NKC|pna2018981568‏
996 ‎‡2  BNF|12691197‏
996 ‎‡2  SUDOC|224723944‏
996 ‎‡2  ISNI|0000000410374057‏
996 ‎‡2  DNB|1030290261‏
996 ‎‡2  LC|no 99027635‏
996 ‎‡2  J9U|987007460244905171‏
996 ‎‡2  DNB|1014456010‏
996 ‎‡2  LC|n 79121627‏
996 ‎‡2  ISNI|0000000072113785‏
996 ‎‡2  BIBSYS|6093383‏
996 ‎‡2  J9U|987007416873805171‏
996 ‎‡2  ISNI|0000000067557613‏
996 ‎‡2  NLA|000061540942‏
996 ‎‡2  NTA|149247354‏
996 ‎‡2  SUDOC|078796709‏
996 ‎‡2  ISNI|0000000083667206‏
996 ‎‡2  CAOONL|ncf11001628‏
996 ‎‡2  LC|n 86864514‏
996 ‎‡2  LC|n 80078291‏
996 ‎‡2  NUKAT|n 2016178093‏
996 ‎‡2  BNF|13206127‏
996 ‎‡2  LC|n 2018187578‏
996 ‎‡2  ISNI|0000000027295225‏
996 ‎‡2  J9U|987007276229205171‏
996 ‎‡2  LC|no2010023841‏
996 ‎‡2  CAOONL|ncf11287839‏
996 ‎‡2  J9U|987007281454205171‏
996 ‎‡2  LC|n 87862418‏
996 ‎‡2  DNB|1147194882‏
996 ‎‡2  BLBNB|000375055‏
996 ‎‡2  NII|DA03597941‏
996 ‎‡2  NUKAT|n 2009147655‏
996 ‎‡2  SUDOC|052476456‏
996 ‎‡2  SUDOC|248984195‏
996 ‎‡2  SUDOC|178746894‏
996 ‎‡2  NLA|000063539807‏
996 ‎‡2  LC|n 92043144‏
996 ‎‡2  NII|DA1024239X‏
996 ‎‡2  LC|n 79066604‏
996 ‎‡2  J9U|987007442227105171‏
996 ‎‡2  LNB|LNC10-000074746‏
996 ‎‡2  BIBSYS|90685448‏
996 ‎‡2  BNF|16200872‏
996 ‎‡2  DNB|1147188343‏
996 ‎‡2  LC|n 2022032485‏
996 ‎‡2  LC|n 80029914‏
996 ‎‡2  ISNI|0000000110765064‏
996 ‎‡2  NKC|xx0205978‏
996 ‎‡2  ISNI|0000000024994186‏
996 ‎‡2  LC|n 90600662‏
996 ‎‡2  LC|n 84008093‏
996 ‎‡2  LC|nr 93033778‏
996 ‎‡2  BIBSYS|90982027‏
996 ‎‡2  CAOONL|ncf11159998‏
996 ‎‡2  LNB|LNC10-000080048‏
996 ‎‡2  NTA|070991308‏
996 ‎‡2  LC|n 2014191110‏
996 ‎‡2  NTA|10538593X‏
996 ‎‡2  RERO|A011515143‏
996 ‎‡2  NTA|073813958‏
996 ‎‡2  DNB|136565514‏
996 ‎‡2  NII|DA07471209‏
996 ‎‡2  DNB|1231395249‏
996 ‎‡2  NUKAT|n 2003072452‏
996 ‎‡2  BIBSYS|90335961‏
996 ‎‡2  ISNI|0000000041480320‏
996 ‎‡2  NII|DA03478170‏
996 ‎‡2  J9U|987007457760205171‏
996 ‎‡2  DNB|138236488‏
996 ‎‡2  ISNI|0000000059614489‏
996 ‎‡2  LC|no2009163960‏
996 ‎‡2  CAOONL|ncf11258849‏
996 ‎‡2  LC|n 2005004353‏
996 ‎‡2  J9U|987007389108005171‏
996 ‎‡2  RERO|A002998452‏
996 ‎‡2  BIBSYS|90570433‏
996 ‎‡2  ISNI|000000003360387X‏
996 ‎‡2  BIBSYS|53109‏
996 ‎‡2  ISNI|0000000378859424‏
996 ‎‡2  BNF|16670636‏
996 ‎‡2  NKC|mub2017961561‏
996 ‎‡2  BAV|495_280330‏
996 ‎‡2  J9U|987007361424305171‏
996 ‎‡2  BIBSYS|90110925‏
996 ‎‡2  RERO|A002998464‏
996 ‎‡2  RERO|A002998461‏
996 ‎‡2  RERO|A002998463‏
996 ‎‡2  RERO|A002998462‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏